Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Meitheal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.
Details : Under the terms of the agreement, Meitheal, through its parent company, will receive exclusive rights to commercialize biosimilar versions of insulin aspart, insulin lispro, and insulin glargine in the U.S. upon approval by the FDA.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
September 21, 2023
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Meitheal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
